GLP-1 weight‑loss drugs: where does potency become a risk?
TL;DR Summary
Eli Lilly’s experimental GLP-1 drug retatrutide produced an average 28% weight loss in obese patients, a striking boost over existing GLP-1 therapies, but doctors warn that greater potency can bring new safety risks; the company expects to file for FDA approval by 2026.
- An experimental GLP-1 pushes the limits of weight loss. There are risks. The Washington Post
- Experimental Drug Yields Dramatic Weight Loss The New York Times
- Eli Lilly says next-generation weight loss drug clears crucial obesity trial CNBC
- Eli Lilly (LLY) Unveils Obesity Data That Could Raise The Bar For The Entire Industry Yahoo Finance
- Eli Lilly touts new weight-loss shot, says stronger than old GLP-1s USA Today
Reading Insights
Total Reads
0
Unique Readers
10
Time Saved
20 min
vs 21 min read
Condensed
99%
4,015 → 43 words
Want the full story? Read the original article
Read on The Washington Post